Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 14, 2018

SELL
$18.47 - $26.39 $231,816 - $331,220
-12,551 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$16.77 - $22.76 $210,480 - $285,660
12,551 New
12,551 $286,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.28B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Drw Securities, LLC Portfolio

Follow Drw Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Drw Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Drw Securities, LLC with notifications on news.